key: cord-0430957-8qcum52t
authors: Kaku, C. I.; Champney, E.; Normark, J.; Johnson, C. E.; Ahlm, C.; Sakharkar, M.; Ackerman, M. E.; Forsell, M. N.; Walker, L. M.
title: Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 prime-boost vaccination
date: 2021-12-14
journal: nan
DOI: 10.1101/2021.12.13.21267598
sha: 47b7430617bcf9cf19ad1b6c9891f29670416fc2
doc_id: 430957
cord_uid: 8qcum52t

Heterologous prime-boost immunization strategies have the potential to augment COVID-19 vaccine efficacy and address ongoing vaccine supply challenges. Here, we longitudinally profiled SARS-CoV-2 spike (S)-specific serological and memory B cell (MBC) responses in individuals receiving either homologous (ChAdOx1:ChAdOx1) or heterologous (ChAdOx1:mRNA-1273) prime-boost vaccination. Heterologous mRNA booster immunization induced significantly higher serum neutralizing antibody and MBC responses compared to homologous ChAdOx1 boosting. Specificity mapping of circulating S-specific B cells revealed that mRNA-1273 booster immunization dramatically immunofocused ChAdOx1-primed responses onto epitopes expressed on prefusion-stabilized S. Monoclonal antibodies isolated from mRNA-1273-boosted participants displayed higher binding affinities and increased breadth of reactivity against variants of concern (VOCs) relative to those isolated from ChAdOx1-boosted participants. Overall, the results provide fundamental insights into the B cell response induced by ChAdOx1 and a molecular basis for the enhanced immunogenicity observed following heterologous mRNA booster vaccination.

Abstract: Heterologous prime-boost immunization strategies have the potential to augment COVID-19 vaccine efficacy and address ongoing vaccine supply challenges. Here, we longitudinally profiled SARS-CoV-2 spike (S)-specific serological and memory B cell (MBC) responses in individuals receiving either homologous (ChAdOx1:ChAdOx1) or heterologous (ChAdOx1:mRNA-1273) prime-boost vaccination. Heterologous mRNA booster immunization induced significantly higher serum neutralizing antibody and MBC responses compared to homologous ChAdOx1 boosting. Specificity mapping of circulating S-specific B cells revealed that mRNA-1273 booster immunization dramatically immunofocused ChAdOx1-primed responses onto epitopes expressed on prefusion-stabilized S. Monoclonal antibodies isolated from mRNA-1273-boosted participants displayed higher binding affinities and increased breadth of reactivity against variants of concern (VOCs) relative to those isolated from ChAdOx1boosted participants. Overall, the results provide fundamental insights into the B cell response induced by ChAdOx1 and a molecular basis for the enhanced immunogenicity observed following heterologous mRNA booster vaccination.

Main text: Multiple safe and effective COVID-19 vaccines have been developed at an unprecedented scale and speed. However, waning vaccine-induced immunity and the emergence of SARS-CoV-2 VOCs with increased neutralization resistance have limited the effectiveness of currently available vaccines (1) (2) (3) . Furthermore, on-going vaccine supply shortages and interruptions have slowed the pace of global mass-vaccination efforts. One significant interruption in vaccine distribution was driven by evidence of rare but serious thrombotic events associated with ChAdOx1 nCoV-19/AZD1222 (hereafter referred to as ChAdOx1) immunization, which led to a halt in ChAdOx1 booster vaccinations in certain age groups (4, 5) .

To fully immunize individuals who received a single dose of ChAdOx1 but were not eligible for a ChAdOx1 boost, several European governments recommended a switch from the clinical trial validated homologous ChAdOx1 booster to heterologous booster vaccination with mRNA-1273 (Moderna) or BNT162b2 (Pfizer/BioNTech). Recent studies have shown that heterologous ChAdOx1/mRNA prime-boost immunization induces higher serum neutralizing antibody titers and confers increased levels of protection relative to homologous ChAdOx1 dosing, but the molecular basis for this difference in immunogenicity remains unknown (6-10).

All COVID-19 vaccines in late-stage clinical trials, approved, or authorized for emergency use are based on the SARS-CoV-2 spike protein, which plays a key role in viral entry and is the only known target for neutralizing antibodies. The S protein exists on the surface of the virion in a metastable prefusion conformation, and binding of the receptor binding domain (RBD) to the host cell receptor, angiotensin converting enzyme 2 (ACE2), triggers shedding of the S1 subunit and transition of the S2 subunit to a highly stable postfusion conformation (11) .

Early structural and biochemical studies demonstrated that a stabilized version of the spike ectodomain that contains two consecutive proline substitutions in the S2 subunit (S-2P) prevents . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 14, 2021. ; https://doi.org/10.1101/2021.12.13.21267598 doi: medRxiv preprint the transition from the prefusion to postfusion state and leads to higher expression levels in vitro and enhanced immunogenicity in animal models (12, 13) . Several COVID-19 vaccines encode S-2P, such that the protein maintains the prefusion conformation and avoids S1 shedding (e.g., mRNA-1273, BNT162b2, and Ad26.COV2.S), whereas others express full-length wild-type (WT) S (e.g. ChAdOx1, Sputnik V, and CoronaVac), which likely leads to expression of both pre-and post-fusion conformations of S. In this study, we comprehensively interrogated serological and circulating B cell responses induced by prime immunization with an adenovirus vector-based vaccine encoding WT S (ChAdOx1) and following either a second dose of ChAdOx1 or an mRNA vaccine expressing S-2P (mRNA-1273).

We recruited 55 healthcare workers at the University Hospital of Northern Sweden receiving either homologous ChAdOx1:ChAdOx1 or heterologous ChAdOx1:mRNA-1273 prime-boost vaccination for blood donation (Table S1 ). The volunteers ranged from 28 to 62 years old, with median ages of 46.5 and 42 for ChAdOx1:ChAdOx1 and ChAdOx1:mRNA-1273 cohorts, respectively. Twenty-seven percent (15/55) of participants were men and 73% (40/55) were women. None of the volunteers had a history of prior infection with SARS-CoV-2. Study participants received one dose of ChAdOx1 and 9-12 weeks later received a second dose of either ChAdOx1 (n=28) or mRNA-1273 (n=27). We collected the first blood sample on the day of booster immunization to analyze ChAdOx1-primed immune responses and a second blood sample 7-10 days following the second dose to study the early secondary B cell response induced by homologous or heterologous booster vaccination (Fig. 1A) .

We first evaluated serum IgG binding activity in the samples collected at both pre-and post-boost timepoints. All participants mounted weak but detectable SARS-CoV-2 S-specific serum IgG binding responses following the first dose of ChAdOx1, and homologous booster . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 14, 2021. ; https://doi.org/10.1101/2021.12.13.21267598 doi: medRxiv preprint vaccination resulted in a small but significant (4.6-fold) increase in serum IgG binding antibodies ( Fig. 1B and Fig. S1 ). In contrast, heterologous booster vaccination with mRNA-1273 led to a dramatic (86-fold) increase in S-specific serum IgG binding responses ( Fig. 1B and Fig. S1 ). Previous studies have shown that cross-reactive MBCs induced by endemic β-CoVs are activated and expanded following primary SARS-CoV-2 infection and mRNA vaccination (14, 15) . To determine whether homologous ChAdOx1:ChAdOx1 and/or heterologous ChAdOx1:mRNA-1273 prime-boost immunization regimens elicited seasonal β-CoV crossreactive antibody responses, we assessed serum IgG binding activity to recombinant OC43 and HKU1 S proteins at both sampling timepoints. At the pre-boost time point, we detected significantly elevated serum antibody titers to both OC43 and HKU1 relative to pre-pandemic sera samples, suggesting recall of pre-existing cross-reactive MBCs induced by seasonal β-CoV infections (Fig. 1F , G). However, this response was not further amplified following homologous or heterologous booster immunization. Thus, it appears that ChAdOx1 prime immunization induces an original antigenic sin-like "back-boost" of cross-reactive antibodies to seasonal β-CoVs in SARS-CoV-2 naïve individuals.

We next evaluated serum neutralizing activity against authentic SARS-CoV-2 D614G, B.1.617.2/Delta, and B.1.351/Beta at both pre-and post-boost timepoints. We selected Delta and Beta VOCs due their prevalence and reduced susceptibility to neutralization by convalescent and . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 14, 2021. ; https://doi.org/10.1101/2021.12.13.21267598 doi: medRxiv preprint vaccinee sera (16, 17) . At 3 months post ChAdOx1 prime immunization, the vast majority of donors (87%) displayed weak or undetectable serum neutralizing activity against SARS-CoV-2 D614G, with 50% neutralization titers ranging from <16 to 66 (Fig. 1H) , and none of the donors showed detectable serum neutralization against Beta or Delta (Fig. 1I, J) . Homologous ChAdOx1 booster immunization resulted in an overall 4.6-fold increase (geometric mean titer = 82) in serum neutralizing activity against SARS-CoV-2 D614G, but neutralizing titers remained at the lower limit of detection in 21% (6/28) of donors (Fig. 1H) . We also detected a small but Previous studies of other viral infections have shown that booster vaccination typically induces a rapid and robust antigen-specific plasmablast response that peaks at approximately day 7 following immunization and accounts for a relatively large proportion of peripheral blood B . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 14, 2021. ; https://doi.org/10.1101/2021.12.13.21267598 doi: medRxiv preprint cells (18, 19) . We therefore assessed the frequency of plasmablasts in peripheral blood 7-10 days following homologous and heterologous booster vaccination (Fig. S2A ). Although we observed modest plasmablast expansion in a subset of ChAdOx1 boosted donors, the median frequency of plasmablasts across all donors was not significantly elevated relative to pre-boost or unpaired pre-pandemic healthy donor samples ( Fig. 2A) . In contrast, heterologous booster immunization induced a robust plasmablast response in almost all donors. In these donors, the frequency of plasmablasts averaged 3% on day 7-10 post-boost and accounted for up to 7% of all CD19 + peripheral blood B cells ( Fig. 2A) .

We next investigated the magnitude and specificities of the S-specific MBC response Correspondingly, booster immunization with mRNA-1273 preferentially expanded WT S/S-2P cross-reactive B cells; these specificities were present in peripheral blood at a median frequency of 0.3% prior to booster immunization and 3.4% following mRNA-1273 boost, while the frequency of WT S-specific cells declined from 0.2% to 0% (Fig. S7) . Thus, in addition to driving a robust expansion of ChAdOx1 prime-induced B cells, heterologous mRNA-1273 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. subunit that is not expressed on S-2P (Fig. 2H ). Consistent with their lack of reactivity with prefusion S, none of the WT S-specific antibodies displayed >50% neutralizing activity against SARS-CoV-2 Wuhan-1 at a 1 µg/ml concentration in an MLV-based pseudovirus assay (20) (Fig. 2I) . We conclude that a relatively large proportion of the SARS-CoV-2 S-specific B cell response induced by homologous ChAdOx1 prime-boost immunization is comprised of nonneutralizing anti-S2 specificities that fail to bind prefusion S.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint To determine whether homologous and heterologous booster vaccination regimens induce distinct B cell responses to prefusion S, we obtained 163 and 252 paired VH and VL sequences from single S2P-reactive B cells from 4 donors in each cohort following ChAdOx1 or mRNA-1273 booster immunization, respectively (Table S2 ). Both booster regimens induced highly diverse B cell responses, with 0 to 8.6% of antibodies belonging to expanded clonal lineages (Fig. S10 ). IGHV3-30 was significantly over-represented in the S-reactive MBC compartment in both ChAdOx1 and mRNA-1273 boosted individuals, as observed previously in antibodies isolated from naturally infected and mRNA vaccinated donors (21, 22) (Fig. S11A) .

The antibodies isolated from both donor cohorts also displayed similar levels of somatic hypermutation (SHM), which ranged from a median of 4-7 and 6-7 VH nucleotide substitutions for ChAdOx1 and mRNA-1273 boosted donors, respectively (Fig. S12A ). In 7 out of 8 donors, >90% of sequences contained somatic mutations, consistent with a recall response mediated by pre-existing memory B cells induced by ChAdOx1 prime immunization (Fig. S12B) .

Furthermore, the overall levels of SHM in the antibodies isolated from both donor cohorts were comparable to that observed in antibodies previously isolated from SARS-CoV-2 convalescent individuals at a similar time point following infection (approximately 3 months), suggesting that the early kinetics of affinity maturation following ChAdOx1 prime immunization may be similar to that of natural infection (Fig. S12) . Overall, the results demonstrate that the genetic features of S-2P-reactive antibodies induced by homologous and heterologous booster vaccination are highly similar, with both groups rich in clonally expanded and somatically mutated sequences. We next measured the binding affinities and neutralizing activities of the S-2P-reactive antibodies induced by homologous and heterologous prime-boost vaccination. Although the antibodies isolated from both cohorts displayed a wide range of Fab binding affinities for . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 14, 2021. ; https://doi.org/10.1101/2021.12.13.21267598 doi: medRxiv preprint recombinant S-2P, those isolated from mRNA boosted donors exhibited overall higher affinities (median K D = 12 nM) compared to those isolated from ChAdOx1 boosted donors (median K D >100 nM) (Fig 3A) . This difference may be associated with expression of WT S by the ChAdOx1 vaccine, which may lead to the activation of B cells with sub-optimal affinity for S-2P. Interestingly, although a relatively large proportion of antibodies isolated from both donor cohorts bound with high affinity to S-2P, only a small subset of binding antibodies (6-13% and 8-21% for ChAdOx1 and mRNA-1273 boosted donors, respectively) displayed >50% neutralizing activity against SARS-CoV-2 Wuhan-1 at a concentration of 1 µg/ml in a pseudovirus neutralization assay (Fig. 3B) . Thus, the neutralizing antibody response represents only a minor fraction of the total prefusion S-reactive binding response induced by both homologous and heterologous prime-boost immunization.

To examine if and how the type of booster immunization impacts B cell immunodominance hierarchy to prefusion S, we evaluated the proportion of S-2P-reactive antibodies directed to the NTD, RBD, and prefusion-stabilized S2 subdomains in each donor from which monoclonal antibodies were isolated. Across the selected donors in both cohorts, we observed relatively similar proportions of antibodies targeting each individual subdomain within prefusion S, although S2-directed antibodies dominated the response in a subset of donors in both groups (Fig. 3C) . Unlike the response to WT S, antibodies targeting conserved epitopes expressed on OC43 and HKU1 S constituted only a minor fraction of the S-2P-reactive response elicited by both ChAdOx1 and mRNA-1273 booster vaccination (5.5% and 4.8%, respectively) ( Fig. S13) . RBD-directed hACE2 blocking antibodies also represented a small proportion of the S-2P-reactive binding response in both donor cohorts, ranging from 3-14% and 2-9% in ChAdOx1:ChAdOx1 and ChAdOx1:mRNA-1273 immunized donors, respectively (Fig. 3C) . As . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Finally, we assessed the RBD-and NTD-directed antibodies isolated from both donor cohorts for reactivity with emerging SARS-CoV-2 VOCs and variants of interest (VOIs). Using a multiplexed bead-based flow cytometry assay, we determined their binding affinities for recombinant RBD and NTDs containing mutations found in the Beta, Gamma, Delta, Kappa, and Lambda VOCs/VOIs. Interestingly, 41% (12/29) of anti-RBD antibodies derived from ChAdOx1 boosted individuals displayed reduced binding activity to >1 VOC/VOI RBD as compared to only 20% (8/40) of antibodies isolated from mRNA-1273 boosted individuals (Fig. 4A and Fig.   S15A ). Correspondingly, for each VOC/VOI RBD tested, a larger proportion of antibodies (80-90%) isolated from mRNA-1273 boosted donors retained binding activity (<2-fold decrease in affinity relative to WT) compared to those derived from ChAdOx1 boosted donors (62-82%) (Fig. 4B) . Furthermore, the mRNA-elicited antibodies bound to both WT and variant RBDs with significantly higher affinities (median K D =1.4-3.7 nM) relative to the ChAdOx1-induced . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 14, 2021. ; https://doi.org/10.1101/2021.12.13.21267598 doi: medRxiv preprint antibodies (median K D =4.9-20.3 nM) (Fig. 4C) , potentially explaining their increased breadth of binding. Consistent with these results, 75% of NTD-directed antibodies isolated from ChAdOx1 boosted donors displayed loss of binding to >1 VOC/VOI NTDs compared to only 53% of antibodies isolated from mRNA-1273 boosted donors (Fig. 4D-E and Fig. S15B ). Similar to the RBD-directed antibodies, the NTD-specific antibodies isolated from mRNA-1273 boosted donors trended toward higher binding affinities across all three VOCs compared to antibodies derived from ChAdOx1 boosted donors (Fig. 4F) . Overall, a significantly larger fraction of anti-RBD and -NTD antibodies (70%) derived from mRNA boosted donors retained reactivity with all three VOC NTDs or RBDs relative to ChAdOx1 boosted donors (51%) (Fig. 4G) . Thus, heterologous mRNA-1273 immunization appears to skew the early secondary B cell response toward higher affinity clones with improved breadth of variant recognition compared to homologous ChAdOx1 immunization.

In conclusion, heterologous ChAdOx1:mRNA-1273 prime-boost immunization induces significantly broader and more potent serum neutralizing antibody and MBC responses against WT SARS-CoV-2 and VOCs relative to homologous two-dose ChAdOx1 vaccination, and this difference appears to be driven by both the magnitude and quality of the early secondary B cell response. Expression of WT S by ChAdOx1 appears to distract the B cell response away from sites of vulnerability present on prefusion S, and homologous booster vaccination further expands these non-functional specificities. In contrast, heterologous booster immunization with mRNA-1273, which encodes S-2P, re-directs the B cell response toward epitopes expressed on prefusion-stabilized S. Furthermore, mRNA-1273 activates B cells with higher affinity for prefusion S and greater breadth of reactivity with VOCs relative to ChAdOx1. The molecular basis for this difference remains to be determined but may be associated with higher cell-surface . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 14, 2021. ; https://doi.org/10.1101/2021.12.13.21267598 doi: medRxiv preprint

Figures S1-S15 Table S1-S2 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Competitive binding with an anti-S2 antibody (ADI-69962), as determined by a BLI competitive sandwich assay, is indicated below the heatmap. (I) Neutralizing activity of WT S-specific antibodies against MLV-SARS-CoV-2 Wuhan-1 at a concentration of 1 µg/ml. A previously described anti-RBD neutralizing antibody (ADG-2) was included as a positive control and is shown in purple (25) . Statistical comparisons between paired prime and boost samples were determined by Wilcoxon pair-matched rank sum test (A and C). Statistical comparisons between vaccination cohorts were determined by two-sided Mann-Whitney U tests (D) and two-sided Kruskal-Wallis test by ranks with subsequent Dunn's multiple comparisons (C and G). *P < . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 14, 2021. ; https://doi.org/10.1101/2021.12.13.21267598 doi: medRxiv preprint 0.05, **P < 0.01, ***P < 0.001, ****P<0.0001. P, Prime; B, Boost; K D App ; apparent equilibrium constant.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The number in the center of the pie indicates the total number of antibodies tested. Statistical significance was determined by two-sided Mann-Whitney U tests (C and F) or Fisher's exact test (G). N.B., non-binding; K D, equilibrium dissociation constant. *P < 0.05.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 14, 2021. ; https://doi.org/10.1101/2021.12.13.21267598 doi: medRxiv preprint

National Study Group for, Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants

Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland

COVID-19 Vaccine-Associated Cerebral Venous Thrombosis in Germany

Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination

Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial

Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity. medRxiv

Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study

Structural insights into coronavirus entry

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

DNA vaccine protection against SARS-CoV-2 in rhesus macaques

Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection

SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2

Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera

Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses

Rapid cloning of high-affinity human monoclonal antibodies against influenza virus

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies

Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies

Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody

Development of an improved microneutralization assay for respiratory syncytial virus by automated plaque counting using imaging analysis

Prolonged evolution of the human B cell response to SARS-CoV-2 infection

High-efficiency yeast transformation using the LiAc/SS carrier DNA/PEG method

Commonality despite exceptional diversity in the baseline human antibody repertoire

We thank study nurse Ida-Lisa Persson and personnel at the Clinical Research Center at Umeå University Hospital for support, enrollment of study subjects, and